the potential role of tigit/lag-3 inhibition in urothelial carcinoma
Published 6 months ago • 39 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
1:56
immune checkpoint inhibitors for urothelial carcinoma: the current landscape
-
2:01
immune checkpoint inhibitors in urothelial bladder cancer
-
3:48
overcoming resistance to immune checkpoint inhibitors in nsclc
-
2:57
immune-checkpoint inhibitors for urothelial cancer
-
1:29
will immune checkpoint inhibitors become the new standard of care for urothelial cancer?
-
0:58
strategies for optimizing immune checkpoint inhibition in urothelial carcinoma
-
4:11
what's next for checkpoint inhibitors in metastatic urothelial bladder cancer?
-
1:15
treating mesothelioma with checkpoint inhibitors
-
2:59
lag-3 antibody combination in immunotherapy-treated melanoma
-
1:39
checkpoint inhibitors for metastatic urothelial cancer
-
6:31
what are checkpoint inhibitors?
-
55:16
targeting tigit to extend immunotherapy benefits to more cancer patients
-
8:35
asco lung cancer roundtable - nsclc - the cityscape trial: anti tigit & immune checkpoint inhibitor
-
0:42
targeting tigit for cancer immunotherapy
-
1:30
emerging immunotherapy beyond checkpoint inhibitors for tnbc
-
0:46
immune checkpoint inhibitors: recent progress and potential biomarkers - 3iv pd-l1 overexpression
-
1:16
dr. he on the potential of immune checkpoint inhibitors in gi cancers
-
1:15
hello tellomak: new trial for t-cell lymphoma
-
0:53
strategies to enhance anti-tumor t cell response to immune checkpoint inhibitors in tnbc